INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
Is the Thrombectomy Market REALLY Overcrowded?
“Thrombectomy” is frequently treated as a single, monolithic category, leading to the misconception that there are too many devices and not enough room to stand out. In practice, thrombectomy spans distinct sub-markets defined by anatomy, indication, access size, and clinical workflow. Key segments include: Acute ischemic stroke (Neurovascular) Pulmonary embolism (PE) Peripheral arterial disease (PAD) Deep vein thrombosis (DVT) Dialysis access thrombosis…